Chimpanzee Genome Holds Key to Human Uniqueness



The chimpanzee genome, which has existed in draft form since the beginning of this year, is poised to reveal new insights into human health and history, according to Svante Paabo. The renowned molecular anthropologist from the University of Leipzig spoke at a plenary session of the annual meeting of HUGO (the Human Genome Organization), which began in Berlin this week.

Paabo and colleagues bring molecular genetic techniques to bear on questions of human evolution. Few advances in that regard are more important than the imminent completion and publication of the chimpanzee genome sequence.

Chimpanzees are our closest relative in evolution, having diverged about 5 million years ago. The genomes of the two species are 98.8 percent identical at the DNA level – a trivial difference in some respects, although Paabo pointed out that this equates to some 40 million variants in total across the genome, not including numerous rearrangements and insertions and deletions.

A fraction of these variations may hold the key to understanding some of the key evolutionary differences that distinguish humans and chimps – areas such as cognition, language, aging, as well as diseases such as Alzheimer’s, schizophrenia, autism, and susceptibility to infectious diseases (AIDS, malaria), as well as cancer.

As these are likely to be polygenic conditions, however, Paabo cautioned that such insights will only emerge with additional genome resources – including the availability of another non-primate genome, the Rhesus macaque – in conjunction with parallel approaches, including studies of the proteome, transcriptome, and the “phenome.” To improve the phenotypic characterization of non-human primates, Paabo’s institute in Leipzig is building a multidisciplinary team to bolster research in primate physiology and social behavior, fields he says have been sorely neglected in the past. “We need to understand the phenotypic differences between chimps and humans,” says Paabo.

Early Insights
Paabo illustrated two examples of early insights into the biology of humanness that preliminary analysis of the chimp sequence has entailed.

First was the field of smell, which is governed by a family of about 1,000 odorant receptors (ORs) in the nose. These ORs transmit nerve signals to the brain that result in the sense of smell. In humans, however, more than half of these receptors are pseudogenes – genes that have withered via mutation and are no longer functional. This contrasts with mice, which have very few pseudogenes. Chimpanzees lie in the middle, having about 30 percent pseudogenes in the OR family. Thus humans are steadily losing functional OR genes – even to the present day. However, there is also evidence for positive selection in at least a subset of OR genes, suggesting that some OR genes may acquire new functions over time.

A second area highlighted by Paabo is the transcriptome. In studies performed using Affymetrix chips, surveys of different regions of the brain have consistently revealed 5-6 percent differences in gene expression. Overall, about 10 percent of the human/chimp genome shows significant difference of expression in some area of the brain. But are these differences functionally significant? To put it another way, are they the result of Darwinian selection or the neutral theory of evolution?

Paabo listed three predictions that would be expected if the sum changes were neutral, rather than the result of selection. However, studies on expression differences between species do not reject any of these predictions, suggesting that the changes seen for the majority of these genes do not appear to have widespread functional significance.

Two other speakers also discussed the pros of comparative genomics. Jenny Marshall-Graves (Australian National University, Canberra) spoke passionately of the virtues of the kangaroo and its “eight gorgeous chromosomes.” Marsupials diverged from eutherian mammals (including humans and primates) about 180 million years ago, and represent the first steps of mammalian evolution. The kangaroo embryo is born about the size of a pea, and is little more than “a mouth, a gut, and a pair of hands to get up to the mother’s pouch,” providing an exciting model for the study of early development. Graves said that a promising candidate gene for pouch development has been identified on the X chromosome. “Maybe we can give pouches to other animals – even humans!” she quipped.

Evan Eichler (Case Western University) highlighted the significance of segmental duplications in the human genome, either on the same chromosome (intrachromosomal) or between chromosomes (interchromosomal). About 150 million bases – the equivalent of a single chromosome – consist of duplicated regions of DNA. Rearrangement of these regions can increase susceptibility to diseases, including cancer.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi whp 2
Managing the Modern Genomics Data Flood
Sponsored by SGI

Managing and storing the perfect storm of multi-disciplined data pouring from next generation sequencers and other omics instruments is a central challenge in life sciences. Discover in this paper how the SGI ArcFiniti storage solution, optimized for unstructured genomics and life sciences data can: 

  • Reduce costs, proactively protect data integrity, and deliver the high performance I/O required for genomics data processing and analysis.  
  • Effectively manage capacities from 156TB to 1.4PB as a disk based, integrated hardware and software platform 


sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .